Explanipedia

348 | LONG‐TERM EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: A RETROSPECTIVE, MONOCENTRIC STUDY FROM BOLOGNA, ITALY Open

Vittorio Stefoni, Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Gabriele Gugliotta , et al. · 2025

SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy Open

Marianna Gentilini, Beatrice Casadei, Cinzia Pellegrini, Lisa Argnani, Gabriele Gugliotta , et al. · 2025

Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice Open

Cinzia Pellegrini, Beatrice Casadei, Alessandro Broccoli, Martina Cantelli, Gabriele Gugliotta , et al. · 2025

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study Open

Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Martina Cantelli, Gabriele Gugliotta , et al. · 2025

No abstract available

Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma Open

Camilla Mazzoni, Lisa Argnani, Beatrice Casadei, Alessandro Broccoli, Giulia Gabrielli , et al. · 2024

First‐line therapy for patients with extranodal marginal zone lymphoma (EMZL) is not well established, except for eradication therapy for Helicobacter pylori in early gastric MZL. Various regimens, for example, locoregional treatment and s…

The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation Open

Alessandro Broccoli, Lisa Argnani, Gabriele Gugliotta, Cinzia Pellegrini, Beatrice Casadei , et al. · 2024

Introduction Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells transplantation (ASCT) is debate…

Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients Open

Gianmarco Bagnato, Vittorio Stefoni, Alessandro Broccoli, Lisa Argnani, Cinzia Pellegrini , et al. · 2024

We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosilate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zeste homolog 1 and 2, and subsequently …

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia Open

Alessandro Broccoli, Lisa Argnani, Laura Nanni, Vittorio Stefoni, Cinzia Pellegrini , et al. · 2023

No abstract available

Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets Open

Claudio Agostinelli, Luca Morandi, Simona Righi, Luigi Cirillo, Marica Iommi , et al. · 2023

The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantation Open

Alessandro Broccoli, Lisa Argnani, Gabriele Gugliotta, Vittorio Stefoni, Cinzia Pellegrini , et al. · 2023

Introduction: Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma; because of its fast growing rate, it often represents a clinical emergency. Intensive treatment approaches are required for adult BL, although a univocal standard …

BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphoma Open

Matteo Carella, Lisa Argnani, Paolo Elia Coppola, Laura Nanni, Stefano Zoli , et al. · 2023

Introduction: One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantation (ASCT) with …

Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitors Open

Cinzia Pellegrini, Beatrice Casadei, Emanuele Sutto, Mariateresa Cantelli, Lisa Argnani , et al. · 2023

Introduction: Programmed death-1 (PD1) blockade is an efficient and safe therapeutic option in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, many patients progress or lose the response to immune checkpo…

Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemia Open

Alessandro Broccoli, Lisa Argnani, Laura Nanni, Ginevra Lolli, Vittorio Stefoni , et al. · 2023

Introduction: Hairy cell leukemia (HCL) patients usually experience multiple disease relapses during the course of their disease. The CD20 antigen is highly expressed on the surface of hairy cells. Single-agent rituximab can be a suitable …

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study Open

Odil Giladi, Gianmarco Bagnato, Marianna Gentilini, Shai Shimony, Oren Pasvolsky , et al. · 2022

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study Open

Odil Giladi, Gianmarco Bagnato, Marianna Gentilini, Shai Shimony, Oren Pasvolsky , et al. · 2022

BEGEV SALVAGE REGIMEN IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE Open

Alice Morigi, Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei , et al. · 2021

Introduction: Any strategy aimed at achieving a minimal disease status, and at specifically obtaining a positron emission tomography-negative status before autologous stem cell transplantation (ASCT) without severe toxicity in primary rela…

Gianmarco Bagnato YOU? Author Swipe